Albert David Ltd is a pharmaceutical company involved in both manufacturing and trading activities. The company focuses on the production of Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms, and Bulk Drugs. It operates in both domestic and international markets, serving customers through domestic sales and exports. With a diverse product portfolio, Albert David Ltd caters to the healthcare industry’s needs by providing high-quality pharmaceutical products. The company’s commitment to excellence and adherence to regulatory standards has enabled it to establish a strong presence in the pharmaceutical sector.
• Albert David Ltd reported Total Income for Q4 FY23 of ₹81 Crore up from ₹74 Crore year on year, a growth of 9%.
• Total Expenses for Q4 FY23 of ₹74 Crore up from ₹67 Crore year on year, a growth of 10%.
• Consolidated Net Profit of ₹3.7 Crore, down 10% from ₹4.1 Crore in the same quarter of the previous year.
• The Earnings per Share is ₹6.54, down 10% from ₹7.31 in the same quarter of the previous year.